Abstract
Aim: To compare the adequacy of different diagnostic procedures for tissue subtyping of NSCLC and analysis of epidermal growth receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) gene fusion and programmed death ligand (PD-L1).
Method: Patients with a final diagnosis of NSCLC undergoing either a fibreoptic bronchoscopy (FOB), enodbronchial ultrasound (EBUS) tranbronchial needle aspiration (TBNA), or a physicina ultrasound-guided biopsy (including lung, chest wall, pleural and neck lymph node) were included. The adequacy of diagsnotic procedures to determine cellular subtype and suitability for molecular testing were assessed.
Results: 492 subjects with NSCLC were identified.289/492 (59%) were male and the median age was 71.6 years. Adenocarcinoma and squamous cell carcinoma accounted for 278/492 and 184/492 cases respectively. Other subtypes were seen in 7/492 cases and 23/492 were not otherwsie specified (NOS). Overall biopsies subtyped NSCLC in between 87-100% of cases., while neck node being the largest group unable to subtyped in 12.7% cases with 8.3% classified as NSCLC-NOS. However, no statistically significant difference was seen across sampling techniques (p=0.323). Therpeutic target testing for EGFR, ALK and PD-L1 was reliable ranging from 73-100% with all Biopsy techniques. No difference was seen across groups in adequacy for EGFR (p=0.09), ALK (p=0.052) and PD-L1 (p sy=0.215) testing.
Conclusion: We found no significant difference in biopsies providing suitable tissue for subtyping in NSCLC, and adequate tissue for therapeutic target testing. Standard biopsy techniques perform equally well in informing on treatment
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4310.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022